# Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

> **NCT05443646** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 55 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** HLX10
- **RADIATION:** hypofractionated radiotherapy
- **RADIATION:** Prophylactic Cranial Irradiation (PCI)

## Key facts

- **NCT ID:** NCT05443646
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-23
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443646, "Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05443646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*